Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer
Authors
Keywords
-
Journal
Annals of Gastroenterological Surgery
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-09-09
DOI
10.1002/ags3.12503
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Colorectal cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
- (2020) Arvind Dasari et al. Nature Reviews Clinical Oncology
- Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study
- (2020) S. J. Schraa et al. BMC CANCER
- The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review
- (2020) Sakti Chakrabarti et al. Cancers
- Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials
- (2020) Romain Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
- (2020) Thierry André et al. LANCET ONCOLOGY
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
- (2019) Thomas Reinert et al. JAMA Oncology
- Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies
- (2019) J Taieb et al. ANNALS OF ONCOLOGY
- JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer
- (2019) Takayuki Yoshino et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial
- (2019) Hideki Ueno et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
- (2019) Jeanne Tie et al. JAMA Oncology
- The Association Between Mutations in BRAF and Colorectal Cancer–Specific Survival Depends on Microsatellite Status and Tumor Stage
- (2018) Hendrik Bläker et al. Clinical Gastroenterology and Hepatology
- A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur–uracil versus surgery alone in stage II colon cancer: SACURA trial
- (2018) Chu Matsuda et al. EUROPEAN JOURNAL OF CANCER
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) Axel Grothey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status
- (2018) Julien Taieb et al. JAMA Oncology
- The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer
- (2018) Hanumant Chouhan et al. JOURNAL OF SURGICAL ONCOLOGY
- What We Know About Stage II and III Colon Cancer: It’s Still Not Enough
- (2017) Alberto Puccini et al. Targeted Oncology
- Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
- (2017) Yujin Kwon et al. Oncotarget
- Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers
- (2017) Frank A. Sinicrope et al. JAMA Oncology
- The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.
- (2017) Ramon Salazar et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer
- (2016) Yu Nakaji et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)
- (2016) Donna Niedzwiecki et al. JOURNAL OF CLINICAL ONCOLOGY
- 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study
- (2016) Takeharu Yamanaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
- (2016) Rachel S Kerr et al. LANCET ONCOLOGY
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
- (2016) Jeanne Tie et al. Science Translational Medicine
- Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes
- (2016) Nan Song et al. JAMA Oncology
- Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
- (2015) Frank A. Sinicrope et al. GASTROENTEROLOGY
- Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery
- (2015) Thomas Reinert et al. GUT
- Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study
- (2015) Eiji Oki et al. International Journal of Clinical Oncology
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial
- (2015) Hans-Joachim Schmoll et al. JOURNAL OF CLINICAL ONCOLOGY
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors
- (2015) S. Kopetz et al. ONCOLOGIST
- Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT
- (2014) H. S. Hochster et al. ANNALS OF ONCOLOGY
- Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147
- (2014) Jocelin Huang et al. Clinical Colorectal Cancer
- Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
- (2014) Wilson I. Gonsalves et al. JNCI-Journal of the National Cancer Institute
- Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
- (2014) Julien Taieb et al. LANCET ONCOLOGY
- Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy
- (2013) Toru Kono et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581
- (2013) Alan P. Venook et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin
- (2013) Greg Yothers et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX®Colon Cancer Assay
- (2011) Kim M Clark-Langone et al. BMC CANCER
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
- (2011) S. Ogino et al. CLINICAL CANCER RESEARCH
- Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue
- (2011) Richard D. Kennedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
- (2011) Greg Yothers et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
- (2011) Richard G. Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
- (2011) F. A. Sinicrope et al. JNCI-Journal of the National Cancer Institute
- An 18-gene signature (ColoPrint®) for colon cancer prognosis
- (2011) Iain B. Tan et al. Nature Reviews Clinical Oncology
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7
- (2010) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer
- (2010) Ramon Salazar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
- (2010) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
- (2009) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now